Click here for the complete Curriculum Vitae.doc

3,799 views
3,604 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
3,799
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
15
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Click here for the complete Curriculum Vitae.doc

  1. 1. CURRICULUM VITAE NAME Peter Alexander Singer, M.D., M.P.H., F.R.C.P.C., FRSC DATE OF CURRICULUM VITAE April 2010 BIOGRAPHICAL INFORMATION 1. Address Director, McLaughlin-Rotman Centre for Global Health University Health Network and University of Toronto Suite 406, South Tower 101 College Street Mailbox 50, Toronto, Ontario, M5G 1L7 CANADA Tel: 416-673-6567 Fax: 416-978-6826 E-mail: peter.singer@mrcglobal.org Website: www.mrcglobal.org 2. Degrees M.D.1984 University of Toronto Internal Medicine M.P.H.1990 Yale University Clinical Epidemiology Advanced Management Certificate 2006 Harvard Business School 3. Employment Current Director, McLaughlin-Rotman Centre for Global Health (2008-) Special Advisor to the Dean of Medicine on Global Health and Innovation (2008-) Professor, Department of Medicine, University of Toronto (1999-) Sun Life Financial Chair in Bioethics, University of Toronto (1997-) Member, Institute of Medical Science, School of Graduate Studies, U of Toronto (1992-) Previous Co-Director and Senior Scientist, Program on Life Sciences, Ethics and Policy at McLaughlin Rotman Centre for Global Health, University Health Network (2006-2008) Co-Director, Canadian Program on Genomics and Global Health (2001-2006) Director, PAHO/WHO Collaborating Centre for Bioethics (2002-2006) Director, MHSc in Bioethics, University of Toronto (1999-2006) Director, University of Toronto Joint Centre for Bioethics (1995-2006) Associate Professor, Department of Medicine, University of Toronto (1994-99) Staff Physician, Department of Medicine, University Health Network (1990-2006) Associate Director, Centre for Bioethics, University of Toronto (1990-95) Associate Member, School of Graduate Studies, University of Toronto (1990-92) Assistant Professor, Department of Medicine, University of Toronto (1989-94) 1
  2. 2. Robert Wood Johnson Clinical Scholar, Yale University School of Medicine (1988-90) Fellow, Center for Clinical Medical Ethics, University of Chicago (1987-88) Resident, Department of Medicine, Toronto General Hospital (1986-87) Intern and Resident, Department of Medicine, Toronto Western Hospital (1984-86) 4. Honours Fellow of TWAS ,The Academy of Sciences for the Developing World, (2009-) Foreign Associate, Institute of Medicine, US National Academies (2008- ) Michael Smith Prize in Health Research ‘Canada’s Health Researcher of the Year’ – Canadian Institutes of Health Research (2007-) Fellow of The Hastings Centre (2007-) Fellow of the Royal Society (Canada) (2007-) Michael Smith Prize in Health Research-Finalist, Canadian Institutes of Health Research (2006) Fellow, Canadian Academy of Health Sciences (2006) Department of Medicine Research Award, University of Toronto (2006) Dales Award, University of Toronto (2005) Award for Excellence, Yale University School of Public Health (2005) Associate Senior Fellow, Massey College (2003-) CIHR Distinguished Investigator (2003-2008) MRC Scientist/CIHR Investigator (1998) Association of Canadian Medical Colleges Young Educators Award (1995) The Toronto Hospital W.H. Anderson Teaching Award (1995) NHRDP National Health Research Scholar (1993) American College of Physicians George Morris Piersol Teaching and Research Scholar (1992) Dr. W. Anderson Memorial Award, The Toronto Hospital (1992) Fellow, American College of Physicians (1991) Canadian Life and Health Insurance Association Medical Scholar (1990) Fellow, Royal College of Physicians and Surgeons of Canada (1998-) Nellie Westerman Prize for Research in Ethics, American Federation for Clinical Research (1988) 5. Professional Affiliations and Activities Board of Governors Current Foreign Secretary and Member, Board of Directors, Canadian Academy of Health Sciences (2008-) Member, Board of Directors, Branksome Hall School (2003-) International Advisory Boards Member of the International Advisory Committee (IAC) of the National Science and Technology Development Agency (NSTDA), Thailand (2010-2012) Member, External Advisory Board, Water Efficient Maize for Africa (2008-) Member of Chicago Global Health Initiative Advisory Board, University of Chicago (2008-) Member of the Scientific and Industry Advisory Board of the BioVeda China Fund (2008-) Advisor to the United Nations Secretary General’s Office on Secretary-General’s Biotechnology Initiative (2006-) Member, Scientific Advisory Board, Grand Challenges in Global Health, Bill & Melinda Gates Foundation (2003-) 2
  3. 3. National Committees Member, Merck Frosst Industry Policy Advisory Committee (2006-) Journal Editorial Boards Member, International Journal of Biotechnology Editorial Board (2007-) Member, International Editorial Advisory Board, Issues in Medical Ethics Member, Editorial Board, The American Journal of Bioethics (2003-) Subject Adviser, Medical Ethics, BioMedCentral (2000-) Associate Editor, Journal of Clinical Ethics (1989-) Previous Board Chair, Branksome Hall School (2005-2007) Member, Ethics Committee, British Medical Journal (2000-2005) Member, International Advisory Board, Bioethics Program, Pan American Health Organization (PAHO) (2003-2006) International Advisor, Indian Council for Medical Research, Fogarty/NIH Bioethics Program (2002-06) Member, Advisory and Executive Committee, International Research Ethics Network for Southern Africa (IRENSA), University of Cape Town (2002-2006) International Advisor, Bangladesh Medical Research Council, Fogarty/NIH Bioethics Program (2002-2006) International Advisor, Aga Khan University, Bioethics Program (2002-2006) Advisory Board Member, Institute of Bioethics, Foundation for Health Sciences, Madrid, (1999-2006) Member, Board of Directors, BIOTECanada (2004-2006) Member, Board of Directors, Canadian Bacterial Diseases Network (2002-2005) Member, Editorial Board, Journal of General Internal Medicine (2000-2005) Member, Board of Directors, (Chair Research Committee) The Change Foundation (2001-2005) Member, Editorial Board, Public Library of Science (PLoS) Medicine (2004-2006) Member, Committee on Advances in Technology and the Prevention of Their Application to Next Generation Biowarfare Threats, US National Academies of Science (2003-06) Consulting Expert in End of Life Care, World Health Organization (2000-01) Associate Editor, Canadian Medical Association Journal (2000-01) Member, Health Salary B Awards Committee (Senior and Distinguished Investigators), Canadian Institutes of Health Research (1999-2002) Advisory Board Member, Theoretical Medicine and Bioethics (1998-2006) Advisory Group Member, Education for Physicians on End of Life Care (EPEC) Project, Institute for Ethics, American Medical Association (1998-2000) Member, Standing Committee on Ethics, Medical Research Council of Canada (1997-2000) Member, Policy Advisory Committee, Cancer Care Ontario (1996-2000) National Advisory Board Member for the project “National Agenda in palliative care research in Canada,” Palliative Care Foundation of Canada (1999) Member, Special Committee to Review the Medical Licensing Examination for its usefulness in evaluating knowledge for end of life care, National Board of Medical Examiners, Philadelphia, PA (1998) Member, Expert Panel on Stents and Abciximab, Cardiac Care Network of Ontario (1996-98) Series Editor, "Bioethics for Clinicians," Canadian Medical Association Journal (1995-2001) Member, Biomedical Ethics Committee, Royal College of Physicians and Surgeons of Canada (1994-99) 3
  4. 4. Coordinator, Bioethics Education Project, Royal College of Physicians and Surgeons of Canada (1995-97) Editorial Board Member, Humane Health Care International (Humane Medicine) (1990-97) International Advisor, Centre for Bioethics, University of Cape Town (1992-95) Ethics Committee, World Organization of Gastroenterology (1990-92) Component 3 Committee, Educating the Future Physicians of Ontario (EFPO) Project (1990-93) 6. University Committees Previous Member, Steering Committee, School of Public Health Sciences (2006-07) Chair, Advisory Committee, University of Toronto Joint Centre for Bioethics (1995-2006) Chair, Alloway Lecture Committee (1995-2006) Chair, Jus Lecture Committee (1995-2006) Member, Task Force on Clinical Faculty, Faculty of Medicine (2002) Executive Committee, Ian Anderson Program for Continuing Education on End-of-Life Care (2000-03) Co-Chair, Bioethicist Search Committee, Centre for Addiction and Mental Health/University of Toronto Joint Centre for Bioethics (1999), Mount Sinai Hospital/University of Toronto Joint Centre for Bioethics (1998), Rehabilitation Institute of Toronto/University of Toronto Joint Centre for Bioethics (1998), Baycrest Centre for Geriatric Care and Sunnybrook Health Science Centre/University of Toronto Joint Centre for Bioethics (1997), Clarke Institute of Psychiatry/University of Toronto Joint Centre for Bioethics (1997), Ontario Cancer Institute/ Princess Margaret Hospital and The Toronto Hospital/University of Toronto Joint Centre for Bioethics (1997), Mount Sinai Hospital/University of Toronto Joint Centre for Bioethics (1996) Chair, Search Committee for Assistant Professor (tenure-track), Program in Molecular Medicine/University of Toronto Joint Centre for Bioethics (1998) Member, Philippa Harris Lecture on Bioethical Issues in Cancer Committee (1997-2002) Executive Committee, Program in Molecular Medicine (1996-2000) Executive Committee, Institute of Medical Science (1995-2004) Co-Chair, University of Toronto Critical Care Medicine Program/Joint Centre for Bioethics Task Force on Appropriate Use of Life-Sustaining Treatments (1997-98) Co-ordinator, End of Life Network, University of Toronto Joint Centre for Bioethics (1995-98) Executive Committee, Collaborative Program in Bioethics (1995-97) Research Committee, Department of Medicine (1993-97) Graduate Studies Committee, Institute of Medical Science (1992-95) Coordinator, Bioethics Seminar, University of Toronto Joint Centre for Bioethics (1990-2001) Curriculum Committee for Undergraduate Medical Ethics, Faculty of Medicine (1990-94) Executive Committee, Centre for Bioethics (1989-95) 7. Hospital Committees Courtesy Staff, Department of Medicine, Division of General Internal Medicine, University Health Network (2007-) Research, Teaching, and University Affairs Committee, University Health Network (2000-02) Xenotransplantation Steering Committee, University Health Network (1998-2000) Medical/Surgical ICU Admission Guidelines Committee, University Health Network (1998-99) Clinical Ethics Committee, The Toronto Hospital (1990-97) Research Committee, Department of Medicine, The Toronto Hospital (1991-1992) Research on Human Subjects Committee, The Toronto Hospital (Western Division) (1990-91) 4
  5. 5. 8. INVITED LECTURES (highly selected) 1. “Ethics of Liver Transplantation with Living Donors.” Meeting of the Ethics Committee of the World Organization of Gastroenterology. Leeds UK (1990) 2. “Liver Transplants with Live Donors.” Symposium on Ethical and Moral Issues in Liver Transplant, World Congress of Gastroenterology. Sydney, Australia. (1990) 3. “Parent to Child Transplantations.” Clinical Ethics Lecture Series, Harvard Medical School. Boston MA (1992) 4. “Life-Sustaining Treatments and Living Wills.” Grand Rounds, Pennsylvania Hospital. Philadelphia PA (1992) 5. “Ethical aspects of the individual patient-doctor relationship.” Workshop on Medical Ethics, World Gastroenterological Organization. Copenhagen, Denmark (1992) 6. Visiting Faculty, First National South African Bioethics Course. University of Capetown. Capetown, South Africa (1993) 7. “Theory and the Clinic: Can They Make Contact?” Kennedy Institute of Ethics, Georgetown University. Washington DC (1994) 8. “Advance Medical Directives.” Wulf Grobin Memorial Lecture, Baycrest Centre for Geriatric Care. North York ON (1994) 9. “Teaching bioethics with standardized patients.” Annual Meeting, Royal College of Physicians and Surgeons of Canada. Toronto ON (1994) 10. “Advance Directives in C.O.P.D.” Clinical Topics in Pulmonary Medicine/Management of End Stage Pulmonary Disease, American Thoracic Society International Conference (1994) 11. “Living Wills in Canada.” Distinguished Speaker Ceremony 1994, Medical Students' Association, University of Alberta. Edmonton AB (1994) 12. “Advance Directives: From Theory to Practice.” The Honourable Mr. Justice O'Byrne/Alberta Heritage Foundation for Medical Research Lecture on Law, Medicine, and Ethics, University of Alberta and University of Calgary. Edmonton and Calgary AB (1995) 13. “Advance Care Planning.” Research Seminar Series, American Association of Retired Persons. Washington DC (1995) 14. “Living Wills: From Legislatures to Living Rooms.” Fourth Annual Labelle Lectureship in Health Services Research, McMaster University. Hamilton ON (1995) 15. “Advance Care Planning.” Medical Grand Rounds, Pennsylvania Hospital. Philadelphia PA (1996) 5
  6. 6. 16. “Teaching and assessing biomedical ethics in medical specialty programs.” Health Care: Outcomes, 65th Annual Meeting, Royal College of Physicians and Surgeons of Canada. Halfax NS (1996) 17. “Teaching Ethics to Residents.” Promoting Professionalism in the Managed Care Era, 20th Annual Yale School of Medicine Affiliated Hospitals Workshop. Bridgeport CT (1996) 18. “Living Wills: From Legislatures to Living Rooms.” Grand Rounds, Yale School of Medicine. New Haven CT (1996) 19. “Dollars, Death, and DNA -- Ethical Challenges at the Frontiers of Health Care.” Canadian Club of Toronto. Toronto ON (1997) 20. “Bioethics: The Coalescence of Science and Law.” 1997 Appellate Court Seminar. Toronto ON (1997) 21. “Resource allocation: beyond evidence-based medicine and cost-effectiveness analysis.” Canadian College of Health Service Executives Conference. Toronto ON (1997) 22. “The Case for Cost Containment.” Janus I. San Juan, Puerto Rico (1998) 23. “Advance Care Planning: From legislatures to living rooms.” The Graham Dick Memorial Lecture Series, Huntington University in Laurentian University of Sudbury. Sudbury ON (1998) 24. “Ethical Issues in Health Care at the End of Life.” Manulife Visiting Scholar, Lakehead University. Thunder Bay ON (1998) 25. “Resource allocation: Beyond evidence-based medicine and cost-effectiveness analysis.” Second International Conference on Priorities in Health Care, British Medical Association. London UK (1998) 26. “Bioethics for Clinicians” Bioética para Clinicos, II Ateneo de Bioética, Instituto de Bioética/Fundación de Ciencias de la Salud. Madrid, Spain (1999) 27. Organized and Taught 3-day Workshop for representatives from all Thai medical schools on “Teaching Bioethics for Clinicians,” Prince of Songkla University. Hat Yai, Thailand (1999) 28. “Qualitative research in end-of-life decision making.” Colloquium on “Epidemiological and Clinical Aspects of End-of-Life Decision-Making,” Amsterdam, The Netherlands (1999) 29. “Priority Setting in Health Care.” “Understanding the New World of Health Care” Course, Harvard University. Cambridge MA (1999) 30. “Terminating Care: Advance Directives.” Department of Clinical Bioethics, National Institutes of Health. Bethesda MD (2000) 31. "Priority setting for new technologies in medicine." Global Program on Evidence Seminar, World Health Organization, Geneva (2000) 32. “Global Health Ethics” Science and Ethics: A Symposium of the Royal Society of Canada, The Canadian Academy of the Sciences and Humanities, Ottawa (2000) 6
  7. 7. 33. “Ethics as a key element for the successful development of nutrigenomics.” The First International Nutrigenomics Conference, The Netherlands (2001) 34. “Genomics and Global Health,” Rockefeller Foundation, New York (2001) 35. “Genomics and Global Health,” Wellcome Trust, London (2001) 36. “Genomics and Global Health,” AAAS/ Science Genome Seminar, Boston (2001) 37. “Genomics and Global Health,” Global Forum for Bioethics Research, Cape Town (2002) 38. “Genomics and Global Health,” World Health Organization Conference, Cuba (2002) 39. Chair, Directions for Health Care V Conference, Toronto (2002) 40. “Genomics and Global Health,” National Policy Research Conference, Ottawa (2002) 41. “Genomics and Global Health,” Creating Knowledge, Strengthening Nations Symposium, University of Toronto, Toronto (2002) 42. “Genomics and Global Health,” New Consumer New Genetics Conference, Berkeley (2002) 43. “Genomics and Global Health,” Fourteenth Annual Dorothy J. MacLean Fellows Conference, The MacLean Center for Clinical Medical Ethics at the University of Chicago, Chicago (2002) 44. “Genomics and Global Health,” International Conference for Priorities in Health, Oslo (2002) 45. “Genomics and Global Health,” Danforth Plant Centre, Monsanto, St. Louis (2002) 46. “Genomics and Global Health Equity: An Example of a Large-Scale Ethics Program,” Keynote Speaker, Canadian Bacterial Diseases Network Annual General Meeting 2003, Calgary (2003) 47. “Global Health Ethics: What Is Our Joint Responsibility In A Global World?,” 2003 Fulbright Scholar Conference, Washington, DC (2003) 48. “Genomics and Global Health,” The Pipeline of Technologies, Global Health Diagnostics Working Group, Bill and Melinda Gates Foundation, Seattle (2003) 49. “Translating Genomic Science for the Social Good,” The Geee! In Genome, Genome Canada, Ottawa (2003) 50. “Genomics and Global Health,” Canadian Genetic Disease Network 12th Annual Scientific Meeting, Kananaskis, Alberta (2003) 51. “Innovations in Global Health: High Tech? Low Tech” STD Innovations,” School of Public Health and Community Health, University of Washington, Seattle (2003) 52. “Genomics and Global Health,” National Research Council of Canada Directors General Meeting, Ottawa (2003) 7
  8. 8. 53. “Top 10 Biotechnologies,” eHealth 2003 (online conference), Cape Town/London, England (2003) 54. “Genomics and Global Health,” University of Cape Town, Cape Town (2003) 55. “Genomics and Global Health,” Friends of CIHR Symposium/Public Forum 2003, Ottawa (2003) 56. “Genomics and Global Health,” St. George’s University, Grenada (2003) 57. “Genomics and Global Health,” BioNorth 2003, Ottawa (2003) 58. “Genomics and Global Health,” World Health Organization, Geneva (2003) 59. “International Issues in Science and Technology,” National Research Council of Canada Leadership Forum, Kanata, Ontario (2003) 60. “Bridging the Gap between Ethics and Science in Nanotechnology,” Nano: from small beginnings to a great future, Frontiers in Research Lectures, Ottawa (2003) 61. “SARS and Ethics,” Grand Rounds, Merle West Medical Center, Klamath Falls, Oregon (2003) 62. “Genome Diplomacy: Canada’s Crucial Role,” Biotechnology, Canada & International Development: The Public Policy Implications, Government of Canada Conference, Ottawa (2004) 63. “Genomics and Global Health”, Netherlands Genomics Initiative: Rotterdam, The Netherlands (2004). 64. “Nanotechnology: Ethical, Economic, Environmental and Social Issues”, US National Academies of Sciences, Washington, D.C. (2004). 65. “Ethical Issue in Science and Technology”, STS Forum, Kyoto, Japan (2004). 66. “Indian Science Conference: Genomics and Global Health:” Ahmedabda, India (2005). 67. “Genomics and Global Health”, Innogen Annual Conference, Edinburgh, Scotland. (2005) 68. ““Shaping knowledge and capacity in developing countries”, Evolution of the Life Science Industries”, University of Ibadan, Nigeria (2005). 69. “Nanotechnology the Developing World”, Nano-business annual conference, NY (2005). 70. (With Mitton C, Gibson J, Martin D, and Donaldson C.) “Ethics & Economics: Towards a comprehensive approach for health care priority setting.” 6th International Conference on the Scientific Basis of Health Services, Montreal (2005) 71. Participant, Taskforce Meeting of Nanotechnology and Ethics. UNESCO Headquarters, Paris (2005) 72. “Genomics and Global Health,” Medical Grand Rounds, Department of Medicine, St. 8
  9. 9. Michael’s Hospital, Toronto (2006) 73. “Genomics and Global Health,” Biotechnology in the Developing World Symposium, Harvard University Medical School, Boston (2006) 74. “Genomics and Global Health,” University of Toronto International Health Program (UTIHP) Seminar Series, Toronto (2006) 75. (with Daar AS.) “Life Sciences and Global Health: The World of the Canadian Program on Genomics and Global Health,” Health Equity Program Lunch, The Rockefeller Foundation, New York (2006) 76. “Genomics, Global Health, and Us,” Department of Medicine 2006 Research Award Winner presentation, University of Toronto (2006) 77. “Ethics: Bioethics in Changing Lives”. Biovision 2006. Alexandria, Egypt. April 2006 78. “How the New Life Sciences Can Respond to Today’s Challenges”. Panel Chair A-2. Biovision 2006. Alexandria, Egypt. April 2006. 79. “Harnessing Biotechnology to Improve Health in Developing Countries”. Institute of Science and Health Network, Harvard University, Boston. May 2006. 80. “Genomics, Global Health, and Us,” Department of Medicine 2006 Research Award Winner Presentation, University of Toronto (June 2006) 81. “ Pharmacogenomics and geographical ancestry: Implications for the development of drugs and global health”. International Forum ‘Bioethics and Global Health’. The National Institute of Genomic Medicine and the School of Philosophy of the National University Autonomous of Mexico INMEGEN (August 2006) 82. “ Delivering Results Through Partnerships” Panel Session held by Merck Frosst on the Aids 2006 Conference theme ‘time to deliver’ (August 2006) 83. “Ethical Social and Cultural (ESC)* Progam for the Grand Challenges in Global Health Initiative. Plenary Talk. The Grand Challenges in Global Health Initiative 2nd Annual Meeting, Washington, DC (October 2006) 84. “Bioethics’ Silver Anniversary” Annual Philippa Harris Lecture on Bioethical Issues in Cancer. Princess Margaret Hospital and the University of Toronto Joint Centre for Bioethics. November 2006 85. “DNA for Peace: Biosecurity and the Developing World”. Dual Use and Code of Conduct Challenges for Scientific Research. Science, Safety and Security- Berlin 2006. (December 2006) 86. “Ethical Issues in Global Health Research”. NIEHS Global Environmental Health Conference, San Francisco. (January 2007) 87. “Biotechnology Industry Capability in Developing Countries”. Guest Lecture in HCMG 890-002: Group Independent Study – “Private Sector Participation in Global Health Development. Wharton Health Care Systems Department. Philadelphia. January 2007. 88. “Using Nanotechnology to Improve Health Care in Developing Countries” Woodrow Wilson Centre, Washington, DC. February 27, 2007. 9
  10. 10. 89. "Life Sciences for Global Health Equity". Family and Geriatric Medicine. James L. Stambaugh, Jr., Lecture Series. University of Louisville. April 2007. 90. PS113F: The UN and Global Governance. Undergraduate class lecture. University of Stanford. May 30, 2007 91. ‘DNA for Peace: The Balance between Biosciences for Development and Security’ International Policy Studies Public Lecture. University of Stanford. May 30, 2007 92. "Human Frontier Science in a Globalizing World". Intergovernmental Conference (IGC) of the Human Frontier Science Program (HFSP) Ottawa. June 14, 2007 93. “Food, Health & Critical Infrastructure: How Secure is the Canadian System". Speaker at the Panel Session organized by International Perspectives and Canadian Institute of International Affairs. June 20, 2007 94. "Research and Innovations in Global Health". 14th National Public Health Colloquium, United Nations University. Kuala Lumpur, Malaysia. September 4-5, 2007. 95. “Ethical Social and Cultural Issues for the Grand Challenges in Global Health Initiative”. Grand Challenges for Global Health Initiative 3rd Annual Meeting. Cape Town, South Africa. October 8, 2007 96. “New Challenges for International Regimes”. Panel session on Biotechnology. University of Stanford. Reno, Nevada. October 19, 2007. 97. “Mars Africa Proposal”. Presentation to the African Development Bank and the Bill and Melinda Gates Foundation. October 25-29, 2007 99. “How Globalization of Life Sciences can make the world a healthier, wealthier and fairer place”. Hart House Lecture Series. University of Toronto. November 7, 2007 100. “The Role of Public Private Partnerships in Global Health: Lessons Learned from the Mectizan Program”. Panel Moderator. Merck & Co. Inc. MaRS Centre. Toronto. 101. “Biosecurity and the Developing World”. Keynote address. Maclean Conference. University of Chicago. November 10, 2007 102. “Ethics and Global Health”. Chair at Panel Session. Maclean Conference. University of Chicago. 103. Alberta Ingenuity Speaker Series. 3 lectures at Edmonton, Lethbridge and Calgary with Abdallah Daar. November 16-21, 2007. 104. “Nanotechnology and the Developing World”. With Dr. Fabio Salamanca-Buentello. University of Toronto STEM (Students for Technology and Engineering in Medicine) December 4, 2007 105. ‘DNA for Peace: Balancing Biosciences for Development and for Security’. Princeton University. January 15, 2008 106. ‘Life Sciences and Global Health: from Lab to Village’. Northwestern University. Kellogg School of Business. January 16, 2008 10
  11. 11. 107. “How the globalization of life sciences can make the world a healthier, wealthier and fairer place” Health and Human Rights Conference 2008. University of Toronto International Health Program. Toronto. January 18, 2008 108. Centre for international Health to welcome in 2008 and information share on University of Toronto's global health initiatives. January 24, 2008. University of Toronto. 109. "Lab to village: ethical, social, cultural, and commercial issues in global health." Guest Lecture in MSc course: Global Health Concentration. Department of Public Health Sciences. University of Toronto. February 4, 2008 110. "Biotechnology and Global Health: From lab to village". Biotechnology and Global Health. Innovatinve Strategies for Achieving the UN’s Global Health Objectives. University of Toronto. February 6, 2008. 111.Lab to village: ethical, social, cultural, and commercial issues in global health Vaccine & Technology Consortium. Medicine in Need. Paris, France Feb 13-14, 2008 112."From lab to village: Harnessing Genomics and Biotechnology to Improve Global Health". University of Geneva Medical School (Centre médical universitaire de Genève). Geneva, Switzerland. February 18, 2008. 113.‘Lab to Village’. MDGs at the North American Model United Nations Conference 2008. Emmanuel College. University of Toronto. February 22, 2008 114.“DNA for Peace – Balancing Biodevelopment and Biosecurity”. The Atlantic Council of Canada. Toronto, Ontario. February 26, 2008 115."Accelerating Health Product Commercialization - A Global Perspective". Ministry of Health Policy Seminar. February 29, 2008 116.“Accelerating Health Product Commercialization in Sub Saharan Africa”. Science with Africa Conference. Addis Ababa, Ethiopia. March 4, 2008 117.‘Inter-Professional Health Care Delivery in Ontario’. "Health Connections: Bringing Together the Partners for Change". Health Professionals day. Aga Khan Health Board for Ontario. March 30, 2008 118."Accelerating Health Innovation in Africa". BioVision Alexandria 2008 Conference. Cairo, Egypt April 12-16, 2008. 119.Global Health Rounds. St. Michael’s Hospital. Toronto. April 21st, 2008 120.“Global Health – From Lab to Village”. St. Clement’s Forty-Minute Forum. St. Clement’s Church, Eglinton Avenue, Toronto. May 4, 2008 121."From Lab to Village: Life Sciences and the Developing World". CIVIC ("Challenging Ismaili Volunteers In Communities") Day hosted by Ismaili Community of Toronto. Markham. May 4, 2008 11
  12. 12. 122.“Life Sciences – From Lab to Village”. International Consortium on Anti-Virals. Trent University. Peterborough. May 5, 2008. 123.“Life Sciences from Lab to Village”. Sentinel Scientific and Board Meeting. Hockley Valley Resort, Orangeville, Ontario. 124.Presentation at the ICES/CEU Conjoint Evaluative Sciences Rounds. Sunnybrook Health Sciences Centre. May 13, 2008 125.Imagination and Research: How do you harness and focus global creativity? Panel member. Hart House, University of Toronto. June 2, 2008. 126.“Imagining the future of Global Health”. 47th Annual Canadian Association for Laboratory Animal Science Symposium. Markham, Ontario. June 10, 2008. 127.“MRC Life Science Convergence Platforms”, The Corporate Council on Africa US-Afica Private Sector Health Forum , Washington, November 21st,2008 128.“Role of Technology/Genomics in Improving Health in Developing World” University of Toronto, Guest Lecture for U of T Students, December 4th, 2008 129.“From Lab to Village: Bioethics and Global Health” Centre for Health Care Ethics, Lakehead University, Thunder Bay, January 14th and 15th 2009 130.“From Lab to Village: Bioethics and Global Health”, University of Penn School of Medicine, Center for Bioethics, Philadelphia January 21st, 2009 131.“From Lab to Village: Can life sciences (help) save the world”?, 2009 NCRTP-HepC PAC meeting, Banff, February 27th, 2009 132.“From Lab to Village: Bioethics and Global Health”, The Gairdner Foundation 50th Anniversary Symposium, Science and Future of Medicine, Vancouver, March 11th, 2009 133."From Lab to Village”, Canadian Institute for Health Research (CIHR) workshop on "Universities, Innovations and Global Medicine Access”, April 21, 2009 134.“From Lab to Village: Can Life Sciences, Ethics, and Commercialization (Help) Save the World?” Global Health and Medical Ethics Faculty Seminar Series, University of Chicago, September 30, 2009 135.“From Lab to Village” : Keystone Symposia, Overcoming the Crisis of TB and AIDS, Oct 20 - Oct 25, 2009, Arusha, Tanzania, 136.“Why Canada should care and what Canada should do?”, 50th Anniversary Gairdner Foundation Global Health Symposium, October 28th, 2009 137."From blue helmets to white lab coats: Science as a Canadian Foreign Policy Priority”, Canadian Science Policy Conference, October 29, 2009 138.“Blue Helmets and White Lab Coats: Science and Innovation as a Foreign Policy Priority for Canada”, Workshop University of Ottawa, November 2, 2009 139.“A Business Plan to Help The ‘Global South’ In Its Fight Against Neglected Diseases”, Health Affairs news briefing, November 3rd, 2009, Washington, DC 12
  13. 13. 140.“Maturation of technologies and critical factors”, Conference on Science against Poverty , April 8-10, 2010, La Granja, Segovia, Spain 141.“From Lab to Village”, Medicine Grand Rounds, April 19-20, 2010, Stanford University, California. 9. PRESENTATIONS BEFORE LEGISLATIVE COMMITTEES OR INQUIRIES Singer PA. A Legislative Committee of The House of Commons of Canada Re: Bill C-203, An Act to Amend the Criminal Code (Terminally Ill Persons). Minutes of the Proceedings and Evidence of Legislative Committee H on Bill C-203, An Act to Amend the Criminal Code (Terminally Ill Persons), Third Session of the Thirty-Fourth Parliament, House of Commons. Government of Canada. Life-Sustaining Treatments, Palliative Care, and the Criminal Code, 28 November, 1991. Singer PA. Consent to Treatment Act, Standing Committee on Administration of Justice. Legislative Assembly for Ontario, First Intersession, 35th Parliament. Official Report of Debates (Hansard. Standing Committee on Administration of Justice, 10 February, 1992, pp. J1682-5. Singer PA. Consent to Treatment Act, Standing Committee on Administration of Justice. Legislative Assembly for Ontario, Second session, 35th Parliament. Official Report of Debates (Hansard). Standing Committee on Administration of Justice, 10th August, 1992, pp. J127-32. Singer PA, Etchells EE. Health Care Consent Act, Standing Committee on Administration of Justice. Legislative Assembly of Ontario, First Session, 36th Parliament. Official Report of Debates (Hansard). Standing Committee on Administration of Justice, 20 February 1996, pp. J458-63. Expert Witness, Krausz Coroner’s Inquiry, Montreal, 1999. Singer PA. Statement to the Senate Standing Committee on Social Affairs Subcommittee Updating “Of Life and Death.” Proceedings of the Subcommittee to Update “Of Life and Death.” Second Session Thirty-Sixth Parliament, 1999-2000, Issue No. 4. 28 February 2000. Singer PA. House of Commons, Presentation to the Standing Committee on Health, Bill C-11, the Human Pathogens and Toxins Act. March 5th, 2009 Singer PA. House of Commons, Appearance as Witness, Bill C-11, An Act to promote safety and security with respect to human pathogens and toxins. March 26th, 2009 10. LIST OF COURSES TAUGHT MSC 3001Y, Foundations Seminar I [1999-2001] MSC 3002Y, Foundations Seminar 2 (Teaching Bioethics) [1999-2001] MSC 3006Y, Independent Study (Writing bioethics articles) [1999-] 13
  14. 14. 11. ACADEMIC HISTORY 1. Research Interests •Life Sciences and the Developing world – “how technologies move from “lab to village” 2.Research Awards Training Awards Period Granting Agency Title of Grant Amount 1987-88 MacLean Center for Clinical Medical Henry J. Kaiser US$25,000 Ethics, University of Chicago Foundation Fellowship (approx) 1988-90 Robert Wood Johnson Foundation Clinical Scholar US$50,000 (approx) 1989 Royal College of Physicians and Detweiler Travel $15,000 Surgeons of Canada Fellowship Career Awards Period Granting Agency Title of Grant Amount 1990-93 Canadian Life and Health Medical Scholarship $150,000 Insurance Association 1992-95 American College of George Morris Piersol Teaching and US$60,000 Physicians Research Scholarship 1993-98 National Health Research National Health Research Scholar $283,562 and Development Program 1998-03 Medical Research Council MRC Scientist/CIHR Invstigator $340,000 of Canada/ Canadian Institutes of Health Research 2003-08 Canadian Institutes of CIHR Distinguished Investigator $350,000 Health Research 2006-08 Ontario Genomics Dales Award $50,000 Institute 2006-08 Canadian Institutes of Michael Smith Prize in Health $100,000 Health Research Research (Finalist) 2007-2012 Canadian Institutes of Michael Smith Prize in Health $500,000 Health Research Research Research Grants Period Granting Agency Title of Grant Amount Role 1990-95 Ontario Ministry of Centre for Bioethics CDN$2,000,000 Co-Investigator Health (PI: Dr. Fred Lowy) 1990-93 Educating Future The Ethics Objective CDN$60,000 Co-Investigator Physicians of Ontario Structured Clinical (approx) (PI: Dr. Jeff (EFPO) Component 3 Examination Turnbull) 1992-93 Alzheimer's Development and CDN$70,000 Co-Investigator 14
  15. 15. Association of Ontario Evaluation of a decisional (PI: Dr. D.W. aid to screen for Molloy) competency to complete a health care directive 1992-94 The Physicians' Preferences for life- CDN$63,200 Principal Services Incorporated sustaining treatment of Investigator Foundation (PSI) patients with HIV-related disease 1992-94 Institute for Clinical Advance directives in CDN$130,698 Principal Evaluative Sciences dialysis Investigator in Ontario (ICES) 1994-96 Agency for Health Impact of advance care CDN$22,377 Thesis Supervisor Care Policy Research directives in terminal (PI: Pat Caulfield) (AHCPR) AIDS care 1994-96 The Physicians' Advance directives in CDN$217,500 Principal Services Incorporated HIV/AIDS Investigator Foundation (PSI) and the Institute for Clinical Evaluative Sciences in Ontario (ICES) 1994-96 The Physicians' Evaluation of CDN$116,540 Co-Investgator Services Incorporated Questionnaires and (PI: Dr. Ed Foundation (PSI) Decisional Aids to Assess Etchells) Patient Capacity to Consent to Life- Sustaining Treatment 1995 National Health Advance directives in CDN$24,390 Principal Research and dialysis: Follow-up study Investigator Development Program (NHRDP) 1995-96 The Physicians' The Acceptability of a CDN$14,856 Research Services Incorporated Cancer Specific Living Supervisor Foundation (PSI) Will in Oncology Patients (PI: Dr. Scott Berry) 1995-96 Agency for Health Chinese seniors' CDN$25,075 Thesis Supervisor Care Policy Research attitudes towards (PI: Kerry (AHCPR) advance directives Bowman) 1996-98 Canadian Foundation Euthanasia and assisted CDN$55,124 Principal for AIDS Research suicide in HIV/AIDS Investigator (CANFAR) 1996-99 Social Sciences and Culture and Ethics in CDN$108,800 Co-Investigator Humanities Research Decision-Making (PI: Prof. Joe Council of Canada Involving Aboriginal Kaufert) (SSHRC) Renal Patients and Their Caregivers 1998-00 Medical Research Resource Allocation for CDN$103,426 Principal Council of Canada New and Emerging Investigator (MRC) Technologies 1998-00 Physicians' Services Resource Allocation for CDN$37,000 Principal Incorporated New and Emerging Investigator Foundation (PSI) Technologies 1999-02 National Health Priority Setting in CDN$149,694 Principal Research and Hospital Programs Investigator 15
  16. 16. Development Program (NHRDP) 2000-02 Change Foundation A Proposal to the Change CDN$90,000 Co-Investigator Foundation to Undertake (PI: J.K. Research on Priority Macdonald) Decision Making in Hospitals in Ontario 2000-04 Fogarty International U of T MHSc in US$1,193,020 Program Leader Centre, National International Bioethics Institutes of Health 2000-07 Ontario Research U of T Program in CDN$5,620,000 Principal Fund Applied Ethics and ($1.885M from Investigator Biotechnology ORF) 2001-05 Genome Canada Canadian Program in CDN$6,353,130 Principal Genomics and Global ($3,176,565 from Investigator Health GC) 2002 Alberta Heritage Incorporating Public CDN$69,530 Co-Investigator Foundation for Values and Technical (PI: Devidas Medical Research Information into Health Menon) Care Resource Allocation Decision-Making 2002-04 Genome Canada Bridging the Emerging CDN$2,830,006 Principal through Genomics Divide ($1,415,003 from Investigator Ontario Genomics GC) Institute 2003-04 Canadian Institutes Genomics and global CDN$62,700 Co-Investigator of Health Research health: Developing a (PI: Abdallah global CIHR network to Daar) address ethical, policy and regulatory issues 2003-08 Canadian Institutes Canadian Priority Setting CDN$986,412 Co-Investigator of Health Research Research Network (PI: Douglas Martin) 2003-04 Canadian Institutes A Global Priority Setting CDN$100,000 Co-Investigator of Health Research Research Network (PI: Douglas Martin) 2004-05 Canadian Institutes Ethical challenges in the CDN$194,850 Co-Investigator of Health Research preparedness and (PI: Ross E.G. response for SARS: An Upshur) interdisciplinary research study 2004-07 Canadian Foundation Information and CDN$1,220,844 Principal for Innovation (CFI) Communication Investigator and Ontario Technology Platform for Innovation Trust Public Engagement to (OIT) Optimize Canadian Innovation 2004-08 Fogarty International U of T MHSc in Bioethics US $1,000,000 Program Leader Center, US National International Stream Institutes of Health 2005-09 Bill & Melinda Gates Addressing Ethical, US$10,000000 Co-Principal Foundation Social and Cultural Investigator Issues Related to the Grand Challenges in 16
  17. 17. Global Health 2006-09 Canadian Institutes Ethics and pandemic CDN$150,000 Co-investigator of Health Research planning: Engaging the voices of the public” 2006-10 Genome Canada Strengthening the Role CDN$10,245,583 Co-Principal through of Genomics and Global Investigator Ontario Genomics Health Institute 2006-10 Ontario Research Strengthening the Role CDN$950,000 Co-Principal Fund of Genomics and Global Investigator Health 2008-12 Bill & Melinda Gates Ethical, Social, Cultural US$2,992,320 Principal Foundation and Commercialization Investigator (ESC2) Program for Water-Efficient Maize for Africa (WEMA) 12. Patents Awarded None 17
  18. 18. 13. PUBLICATIONS Journal Articles 1.Singer P, Wanless I, Silver H, Keating A. Pulmonary tumor emboli, microangiopathic hemolytic anemia and dyspnea in disseminated cancer. The Cancer Journal 1986; 1: 76-8. 2.Singer PA. Should doctors kill patients? Canadian Medical Association Journal 1988; 138: 1000-1. 3.Singer PA, Lantos JD, Whitington PF, Broelsch CE, Siegler M. Equipoise and the ethics of segmental liver transplantation. Clinical Research 1988; 36: 539-45. 4.Siegler M, Singer PA. Clinical ethics consultation: Godsend or "God Squad"? American Journal of Medicine 1988; 85: 759-60. 5.Lowance DC, Singer PA, Siegler M. Withdrawal from dialysis: An ethical perspective. Kidney International 1988; 34: 124-35. 6.Ho Ping Kong H, Singer PA, Lynch A, Siegler M. Symposium: teaching and learning clinical medical ethics during residency training. Annals of the Royal College of Physicians and Surgeons of Canada 1988; 21: 423-6. 7.Grim PS, Singer PA, Gramelspacher GP, Feldman T, Childers RW, Siegler M. Informed consent in emergency research: Prehospital thrombolytic therapy for acute myocardial infarction. Journal of the American Medical Association 1989; 262: 252-5. 8.Miles SH, Singer PA, Siegler M. Conflicts between patients' requests to forgo treatment and the policies of health care facilities. New England Journal of Medicine 1989; 321: 48-50. 9.Lantos JD, Singer PA, Walker RM, Gramelspacher GP, Shapiro GR, Sanchez-Gonzalez MA, Stocking CB, Miles SH, Siegler M. The illusion of futility in clinical practice. American Journal of Medicine 1989; 87: 81-4. 10.Singer PA, Siegler M, Whitington PF, Lantos JD, Emond JC, Thistlethwaite JR, Broelsch CE. Ethics of liver transplantation with living donors. New England Journal of Medicine 1989; 321: 620-2. 11.Kinsella TD, Singer PA, Siegler M. Legalized active euthanasia: an Aesculapian tragedy. American College of Surgeons Bulletin December 1989; 74: 6-9, 56. 12.Singer PA. A review of public policies to procure and distribute kidneys for transplantation. Archives of Internal Medicine 1990; 150: 523-7. 13.Siegler M, Pellegrino ED, Singer PA. Clinical medical ethics. Journal of Clinical Ethics 1990; 1: 5-9. 14.Singer PA, Siegler M, Lantos JD, Emond JC, Whitington PF, Thistlethwaite JR, Broelsch CE. The ethical assessment of innovative therapies: liver transplantation using living donors. Theoretical Medicine 1990; 11: 87-94. 15.Singer PA, Siegler M. Euthanasia -- A Critique. New England Journal of Medicine 1990; 322: 1881-3. 18
  19. 19. 16.Singer PA, Siegler M, Pellegrino ED. Research in clinical ethics. Journal of Clinical Ethics 1990; 1: 95-9. 17.Pellegrino ED, Siegler M, Singer PA. Teaching clinical ethics. Journal of Clinical Ethics 1990; 1: 175-80. 18.Singer PA, Miles SH, Siegler M. Computer searches of the medical ethics literature. Journal of Clinical Ethics 1990; 1: 195-8. 19.Singer PA, Tasch ES, Stocking CB, Rubin S, Siegler M, Weichselbaum M. Sex or survival? Tradeoffs between quality and quantity of life. Journal of Clinical Oncology 1991; 9: 328-34. 20.Cohen R, Singer PA, Rothman AI, Robb A. Assessing competency to address ethical issues in medicine. Academic Medicine 1991; 66: 14-5. 21.Singer PA, Pellegrino ED, Siegler M. Ethics committees and consultants. Journal of Clinical Ethics 1991; 1: 263-7. 22.White BD, Siegler M, Singer PA, Iserson KV. What Does Cruzan Mean to the Practising Physician? Archives of Internal Medicine 1991; 151: 925-8. 23.Singer PA. The Case of Nancy Cruzan, the Patient Self-Determination Act and Advance Directives in Canada. Humane Medicine 1991; 7: 225-7. 24.Singer PA, Lowy FH. Refusal of life-sustaining treatment, the Malette case, and decision making under uncertainty. Annals of the Royal College of Physicians and Surgeons of Canada 1991; 24: 401-3. 25.Singer PA. How Green is Your Grass? A Comparative Analysis of the U.S. and Canadian Health Care Systems. Humane Medicine 1991; 7: 47-53. [Report of a Conference] 26.Pellegrino ED, Siegler M, Singer PA. Future directions in clinical ethics. Journal of Clinical Ethics 1991; 2: 5-9. 27.Shaw LR, Miller JD, Slutsky AS, Maurer JR, Puskas JD, Patterson GA, Singer PA. Ethics of Lung Transplantation with Live Donors. Lancet 1991; 338: 678-81. 28.Kodish E, Lantos J, Stocking C, Singer PA, Siegler M, Johnson FL. Bone Marrow Transplantation for Sickle Cell Disease: A Study of Parents' Decisions. New England Journal of Medicine 1991; 325: 1349-53. 29.Singer PA, Siegler M. Elective use of life-sustaining treatments. Advances in Internal Medicine 1991; 36: 57-79. 30.Singer PA, End Stage Renal Disease Network of New England. Nephrologists' Experience With and Attitudes Towards Decisions to Forego Dialysis. Journal of the American Society of Nephrology 1992; 2: 1235-40. 31.Advance Directives Seminar Group. Advance Directives: Are They An Advance. Canadian Medical Association Journal 1992; 146: 127-34. 32.Singer PA, Siegler M. Advancing the Cause of Advance Directives. Archives of Internal 19
  20. 20. Medicine 1992; 152: 22-4. 33.Singer PA, Lowy FH. Rationing, Patient Preferences and Cost of Care at the End of Life. Archives of Internal Medicine 1992; 152: 478-80. 34.Singer PA, Choudhry S. Ontario's proposed new laws regarding consent to treatment: I. Consent and capacity, substitute decisions, advance directives, and emergency treatment. Canadian Medical Association Journal 1992; 146: 829-32. 35.Choudhry S, Singer PA. Ontario's proposed new laws regarding consent to treatment: II. Advocacy. Canadian Medical Association Journal 1992; 146: 1165-9. 36.Singer PA, Nash C, Meslin EM, Lowy FH. The University of Toronto Centre for Bioethics. Humane Medicine 1992; 8: 219-24. 37.Hughes DL, Singer PA. Family physicians' attitudes towards advance directives. Canadian Medical Association Journal 1992; 146: 1937-44. 38.Wright JG, Singer PA. HIV Seropositive Surgeons: informed consent and public health policy. Canadian Medical Association Journal 1992; 147: 29-31. 39.Fish A, Singer PA. Nancy B: Decisions to forgo life-sustaining treatment and the Criminal Code. Canadian Medical Association Journal 1992; 147: 637-42. 40.Singer PA. The University of Toronto Centre for Bioethics Living Will. Ontario Medical Review January 1993: 35-41. 41.Singer PA, Cohen R, Robb A, Rothman A. The Ethics Objective Clinical Examination (OSCE). Journal of General Internal Medicine 1993; 8: 23-8. 42.Kohut N, Singer PA. Advance Directives in Family Practice. Canadian Family Physician 1993; 39: 1087-93. 43.Singer PA, Choudhry S, Armstrong J. Public Opinion Regarding Consent to Treatment. Journal of the American Geriatrics Society 1993; 41: 112-6. 44.Sam M, Singer PA. Canadian outpatients and advance directives: poor knowledge, little experience, but positive attitudes. Canadian Medical Association Journal 1993; 148: 1497-1502. 45.Charland LC, Singer PA. Bill C-203: a post-mortem analysis of "right to die" legislation that died. Canadian Medical Association Journal 1993; 148: 1705-8. 46.Singer PA, Feinstein AR. Graphical Display of Categorical Data. Journal of Clinical Epidemiology 1993; 46: 231-6. 47.Thomsen OØ, Wulff HR, Martin A, Singer PA. What do gastroenterologists in Europe tell cancer patients? Lancet 1993; 341: 473-6. 48.White BD, Singer PA, Siegler M. Continuing Problems with Patient Self-Determination. American Journal of Medical Quality 1993; 8: 187-93. 49.Silberfeld M, Nash C, Singer PA. Capacity to Complete An Advance Directive. Journal of the American Geriatric Society 1993; 41: 1141-3. 20
  21. 21. 50.Singer PA. The University of Toronto Centre for Bioethics Living Will. Humane Medicine 1993; 9: 263. 51.Singer PA. The University of Toronto Centre for Bioethics Living Will. Estates & Trusts Journal 1994; 13: 287-96. 52.Reinders M, Singer PA. Which Advance Directives Do Patients Prefer? Journal of General Internal Medicine 1994; 9: 49-51. 53.Rasooly I, Lavery JV, Urowitz S, Choudhry S, Seeman N, Meslin EM, Lowy FH, Singer PA. Hospital Policies on Life-Sustaining Treatments and Advance Directives in Canada. Canadian Medical Association Journal 1994; 150: 1265-70. 54.Choudhry NK, Wright JG, Singer PA. Outcome Rates for Individual Physicians: Concerns About Accuracy, Completeness, and Consequences of Disclosure. Surgery 1994; 115: 406-8. 55.Singer PA. Disease-specific advance directives. Lancet 1994; 344: 594-6. 56.Mendelssohn DC, Singer PA. Advance Directives in Dialysis. Advances in Renal Replacement Therapy 1994; 1: 240-50. 57.Singer PA. Advance Directives in Palliative Care. Journal of Palliative Care 1994; 10: 111-6. 58.Singer PA, Robb A, Cohen R, Norman J. Evaluation of a Multicentre Ethics Objective Structured Clinical Examination. Journal of General Internal Medicine 1994; 9: 690-2. 59.Choudhry NK, Ma JJK, Rasooly I, Singer PA. Long-Term Care Facility Policies on Life- Sustaining Treatments and Advance Directives in Canada. Journal of the American Geriatric Society 1994; 42: 1150-3. 60.Martin DK, Singer PA, Siegler M. Ethical Considerations in Liver Transplantation. In: Boyer JL, Ockner RK, eds. Progress in Liver Diseases 1994; 12: 215-29. 61.Crelinsten GL, Singer PA, Kenny NP for the Royal College of Physicians and Surgeons of Canada Biomedical Ethics Committee. Presentation to the Special Senate Committee on Euthanasia and Assisted Suicide. Annals of the Royal College of Physicians and Surgeons of Canada 1994; 27: 459-61. 62.Emanuel LL, Danis M, Pearlman RA, Singer PA. Advance Care Planning as a Process: Structuring the Discussions in Practice. Journal of the American Geriatric Society 1995; 43: 440-6. 63.Martin DK, Meslin EM, Kohut N, Singer PA. The Incommensurability of Research Risks and Benefits: Practical Help for Research Ethics Committees. IRB 1995; 17: 8-10. 64.Gordon M, Singer PA. Decisions and Care at the End of Life. Lancet 1995; 346: 163-6. 65.Singer PA. Advance directive fallacies. Health Law in Canada 1995; 16(1): 5-9. 66.Singer PA, Choudhry S, Armstrong J, Meslin EM, Lowy FH. Public Opinion Regarding End of Life Decisions: Influence of prognosis, practice, and process. Social Sciences & Medicine 1995; 41: 1517-21. 21
  22. 22. 67.Mendelssohn D, Kua BT, Singer PA. Referral for Dialysis in Ontario. Archives of Internal Medicine 1995; 155: 2473-8. 68.Singer PA, Thiel EC, Naylor CD, Richardson RMA, Llewellyn-Thomas H, Goldstein M, Saiphoo C, Uldall R, Kim D, Mendelssohn DC. Life-Sustaining Treatment Preferences of Hemodialysis Patients: Implications for Advance Directives. Journal of the American Society of Nephrology 1995; 6: 1410-7. 69.Singer PA. Advance directives in COPD. Monaldi Archives for Chest Disease 1995; 50: 62-3. 70.Mullen M, Kohut N, Sam M, Blendis L, Singer PA. Access to adult liver transplantation in Canada: a survey and ethical analysis. Canadian Medical Association Journal 1996; 154: 337-42. 71.Singer PA, Robb A, Cohen R, Norman G, Turnbull J. Performance-based assessment of clinical ethics: The ethics objective clinical examination. Academic Medicine 1996; 71: 495-8. 72.Molloy DW, Silberfeld M, Darzins P, Guyatt GH, Singer PA, Rush B, Bédard M, Strang D. Measuring Capacity to Complete an Advance Directive. Journal of the American Geriatric Society 1996; 44: 660-4. 73.Cecioni R, Singer PA. Un Approccio Canadese al Testamento di Vita: Il Consent to Treatment Act Dell'Ontario (A Canadian approach to living wills: The Consent to Treatment Act in the Province of Ontario). Rivista Italiana di Medicina (Italian Journal of Legal Medicine) 1996; 18: 1275-93. 74.Singer PA. Bioethics for Clinicians: Introduction. Canadian Medical Association Journal 1996: 155: 189-90. 75.Etchells E, Sharpe G, Walsh P, Williams JR, Singer PA. Bioethics for Clinicians: 1. Consent. Canadian Medical Association Journal 1996; 155: 177-80. 76.Etchells E, Sharpe G, Burgess M, Singer PA. Bioethics for Clinicians: 2. Disclosure. Canadian Medical Association Journal 1996; 155: 387-91. 77.Etchells E, Sharpe G, Elliot C, Singer PA. Bioethics for Clinicians: 3. Capacity. Canadian Medical Association Journal 1996; 155: 657-61. 78.Etchells E, Sharpe G, Dykeman MJ, Meslin EM, Singer PA. Bioethics for Clinicians: 4. Voluntariness. Canadian Medical Association Journal 1996; 155: 1083-6. 79.Lazar N, Greiner GG, Robertson G, Singer PA. Bioethics for Clinicians: 5. Substitute Decision Making. Canadian Medical Association Journal 1996; 155: 1435-7. 80.Singer PA, Robertson G, Roy DJ. Bioethics for Clinicians: 6. Advance Care Planning. Canadian Medical Association Journal 1996; 155: 1689-92. 81.Hébert PC, Hoffmaster B, Glass KC, Singer PA. Bioethics for Clinicians: 7. Truth telling. Canadian Medical Association Journal 1997; 156: 225-8. 82.Kleinman I, Baylis F, Rodgers S, Singer PA. Bioethics for Clinicians: 8. Confidentiality. 22
  23. 23. Canadian Medical Association Journal 1997; 156: 521-4. 83.Lavery JV, Dickens BM, Boyle JM, Singer PA. Bioethics for Clinicians: 11. Euthanasia and Assisted Suicide. Canadian Medical Association Journal 1997; 156: 1405-8. 84.McKneally MF, Dickens BM, Meslin EM, Singer PA. Bioethics for Clinicians: 13. Resource Allocation. Canadian Medical Association Journal 1997; 157: 163-7. 85.Etchells E, Katz MR, Shuchman M, Wong G, Workman S, Choudhry NK, Craven J, Singer PA. Accuracy of Clinical Impressions and Mini-Mental State Exam Scores for Assessing Capacity to Consent to Major Medical Treatment. Psychosomatics 1997; 38: 239-45. 86.Lavery JV, Singer PA. The Supremes Decide About Assisted Suicide: What Should a Doctor Do? Canadian Medical Association Journal 1997; 157: 405-6. 87.Kohut N, Sam M, O'Rourke K, MacFadden DK, Salit I, Singer PA. Stability of Treatment Preferences: Although Most Preferences Do Not Change, Most People Change Some of Their Preferences. Journal of Clinical Ethics 1997; 8: 124-35. 88.Singer PA. Resource allocation: Beyond evidence-based medicine and cost- effectiveness analysis. ACP Journal Club 1997; 127(3): A16-8. 89.Singer PA, Thiel EC, Salit I, Flanagan W, Naylor CD. The HIV-specific advance directive. Journal of General Internal Medicine 1997; 12: 729-35. 90.Singer PA, Zlotnik Shaul R. Resource Allocation in Coronary Revascularization. Canadian Journal of Cardiology 1997; 13 (Suppl D): 64-6. 91.Almond D, Chisholm R, Cohen E, Higginson L, Matthews M, McKenzie N, Savage R, Singer PA, Sue-Chan S, Vimr MA. CCN Expert Panel on Intracoronary Stents: Final Recommendations, January 1997. Willowdale, ON: Cardiac Care Network of Ontario, 1997, 46 pp. 92.Berry S, Singer PA. The Cancer Specific Advance Directive. Cancer 1998; 82: 1570-1577. 93.Singer PA, Martin DK, Lavery JV, Thiel EC, Kelner M, Mendelssohn DC. Reconceptualizing advance care planning from the patient's perspective. Archives of Internal Medicine 1998; 158: 879-84. 94.King SB III, Ullyot DJ, Basta L, Bove AA, Conti CR, Jenemann AH, Singer PA. Task Force 2: Application of Medical and Surgical Interventions Near the End of Life. Journal of the American College of Cardiology 1998; 31: 933-42. 95.Singer PA. Legislated Rights Advice: A Cautionary Tale. Health Law in Canada 1998; 18: 133-6. 96.Singer PA, MacDonald N. Bioethics for Clinicians: 15. Quality End of Life Care. Canadian Medical Association Journal 1998; 159: 159-62. 97.Weijer C, Singer PA, Dickens BM, Workman S. Bioethics for Clinicians: 16. Dealing with demand for "inappropriate" treatment: Medical futility and other approaches. Canadian Medical Association Journal 1998; 159: 817-21. 23
  24. 24. 98.Singer PA, Mapa J. Ethics of Resource Allocation: Dimensions for Healthcare Executives. Hospital Quarterly 1998; 1(4): 29-31. 99.Lemmens T, Singer PA. Bioethics for Clinicians: 17. Conflict of Interest in Research, Education, and Patient Care. Canadian Medical Association Journal 1998; 159: 960-5. 100.Martin DK, Thiel EC, Singer PA. A new model of advance care planning: Observations from people with HIV. Archives of Internal Medicine 1999; 159: 86-92. 101.Singer PA, Martin DK, Kelner MJ. Quality End of Life Care: Patients' Perspectives. Journal of the American Medical Association 1999; 281: 163-8. 102.Etchells E, Darzins P, Silberfeld M, Singer PA, McKenny J, Naglie G, Katz M, Guyatt G, Molloy W, Strang D. Assessment of patient capacity to consent to treatment: Agreement between treating clinicians, mini mental state scores, and expert assessments. Journal of General Internal Medicine 1999; 14: 27-34. 103.Aikman PJ, Thiel EC, Martin DK, Singer PA. Proxy, Health and Personal Care Preferences: Implications for End of Life Care. Cambridge Quarterly of Healthcare Ethics 1999; 8: 200-10. 104.Singer PA. "Springing Back": Advance Care Planning in Dialysis. American Journal of Kidney Disease 1999; 33: 980-91. 105.Martin DK, Singer PA. Bone Marrow Transplant for Rheumatoid Arthritis: The Costs of a Cure. Journal of Rheumatology 1999; 26: 1217-8. 106.Ikonomidis S, Singer PA. Autonomy, Liberalism, and Advance Care Planning. Journal of Medical Ethics 1999; 25: 522-7. 107.Hawryluck L, Harvey W, Lemieux-Charles L, Singer PA. Consensus Guidelines on the Use of Analgesia and Sedation in Dying Pediatric Intensive Care Unit (PICU) Patients. Critical Care Medicine 1999; 27: A83. 108.Singer PA. Medical journals are dead – Long live medical journals. Canadian Medical Association Journal 2000; 162: 517-8. 109.Ho VWK, Thiel EC, Rubin HR, Singer PA. The Effect of Advance Care Planning on Completion of Advance Directives and Patient Satisfaction in People with HIV/AIDS. AIDS Care 2000; 12: 97-108. 110.Bowman KW, Martin DK, Singer PA. Quality End-of-Life Care. Journal of Evaluation in Clinical Practice 2000; 6: 51-61. 111.Singer PA. Recent Advances in Medical Ethics. British Medical Journal 2000; 321: 282-285. 112.Benatar SR, Singer PA. A new look at international research ethics. British Medical Journal 2000; 321: 824-6. 113.Singer PA. When shall we be free? Only when incentives in science are designed to reward rather than penalize open access publication. BioMedCentral News and Views 2001; 1: 14; reprinted in Journal of Electronic Publishing 2000; 6 (2). 24
  25. 25. 114.Singer PA, Todkill AM. Bioethics for clinicians: continuing the series. Canadian Medical Association Journal 2000; 163: 833. 115.Martin DK, Emanuel LL, Singer PA. Planning for the end of life. Lancet 2000; 356: 1672-6. 116.Singer PA, Martin DK, Giacomini M, Purdy L. Priority setting for new technologies in medicine: qualitative study. British Medical Journal 2000; 321: 1316-8. 117.Singer PA, Daar AS. Avoiding Frankendrugs. Nature Biotechnology 2000; 18: 1223. 118.Singer PA, Martin DK, Bowman KW. Quality end of life care: Where do we go from here? Journal of Palliative Medicine 2000; 3: 403-6. 119.Singer PA, Barker G, Bowman KW, Harrison C, Kernerman P, Kopelow J, Lazar N, Weijer C, Workman S. Hospital policy on appropriate use of life-sustaining treatment. Critical Care Medicine 2001; 29: 187-91. 120.Bowman KW, Singer PA. Chinese Seniors' Perspectives on End-of-Life Decisions. Social Science & Medicine 2001; 53(4): 455-64. 121.Singer PA. Top 10 reasons why print journals have a future [Q & A]. Journal of Health Services Research and Policy 2001; 6(3): 192. 122.McKneally MF, Singer PA. Bioethics for Clinicians: 25. Teaching bioethics in the clinical setting. Canadian Medical Association Journal 2001; 164: 1163-7. 123.Singer PA. Learning to love mistakes. British Medical Journal 2001; 322: 1236. 124.Pauls M, Singer PA, Dubinsky I. Communicating Advance Directives from Long-Term Care Facilities to Emergency Departments - A Qualitative Study of Health-Care Providers. Journal of Emergency Medicine 2001; 21(1): 83-9. 125.Singer PA, Pellegrino ED, Siegler M. Clinical ethics revisited. BioMedCentral Medical Ethics 2001; 2(1): 1. 126.Singer PA, Benatar SR. Beyond Helsinki: A vision for global health ethics. British Medical Journal 2001; 322: 747-8. 127.D’Souza D, Martin DK, Bezjak A, Purdy L, Singer PA. Waiting lists for radiation therapy: A case study. BioMedCentral Health Services Research 2001; 1: 3. 128.Lavery JV, Boyle J, Dickens BM, Maclean H, Singer PA. Origins of the desire for euthanasia and assisted suicide in people with HIV-1 or AIDS: a qualitative study. Lancet 2001; 358: 362-7. 129.Martin DK, Pater JL, Singer PA. Priority Setting Decisions for New Cancer Drugs: What rationales are used? Lancet 2001; 358: 1676-81. 130.Singer PA, Daar AS. Harnessing Genomics and Biotechnology to Improve Global Health Equity. Science 2001; 294: 87-9. 131.Singer PA. Vision is needed to address problem of global health information. [Letter to the editor.] British Medical Journal 2001; 322: 673-4. 25
  26. 26. 132.Singer PA. Minimal refereeing will lead to global equity of information. [Letter to the Editor.] British Medical Journal 2001; 323(7304): 111-2. 133.Singer PA, Bowman K. Quality end-of-life care: A global perspective. BioMedCentral Palliative Care 2002; 1: 4. 134.Singer PA, Bowman KW. Quality care at the end of life: Should be recognised as a global problem for public health and health systems. British Medical Journal 2002; 324: 1291-2. 135.Singer PA. Rx for Reform. Foreign Policy 2002; May-June (Issue 130): 76-7. [Between the Lines] 136.Gibson JL, Martin DK, Singer PA. Priority setting for new technologies in medicine: A transdisciplinary study. BioMedCentral Health Services Research 2002; 2: 14. 137.Hawryluck L, Harvey WRC, Lemieux-Charles L, Singer PA. Consensus guidelines on analgesia and sedation in dying Intensive Care Unit patients. BioMedCentral Medical Ethics 2002; 3: 3. 138.Martin DK, Giacomini M, Singer PA. Fairness, Accountability for Reasonableness, and the Views of Priority Setting Decision Makers. Health Policy 2002; 61: 279-90. 139.Daar AS, Thorsteinsdóttir H, Martin DK, Smith AC, Nast S, Singer PA. Top 10 Biotechnologies for Improving Health in Developing Countries. Nature Genetics 2002; 32: 229-32. 140.Martin DK, Abelson J, Singer PA. Participation in health care priority setting through the eyes of the participants. Journal of Health Services Research & Policy 2002; 7: 222-9. 141.Singh JA, Singer PA. Isolationism is not the answer to bioterrorism: Increased support for research in the developing world would be a better strategy. Nature 2002; 420: 605. [Letter to Nature] 142.Choudhry N, Choudhry S, Singer PA. CPR for the DNR: The Role of the Limited Aggressive Therapy Order. Annals of Internal Medicine 2003; 138: 65-8. 143.Singer PA. Intimate examinations and other ethical challenges in medical education. British Medical Journal 2003; 326: 62-3. [Editorial] 144.Benatar SR, Daar AS, Singer PA. Global Health Ethics: The rationale for mutual caring. International Affairs 2003; 79: 107-38. 145.Mnyusiwalla A, Daar AS, Singer PA. “Mind the Gap”: Science and Ethics in Nanotechnology. Nanotechnology 2003; 14: R9-13. 146.Dowdeswell E, Daar AS, Singer PA. Bridging the Genomics Divide. Global Governance Journal 2003; 9: 1-6. 147.Paus Jenssen A, Singer PA, Detsky AS. Ontario's Formulary Committee: How Recommendations Are Made. PharmacoEconomics 2003; 21: 285-94. 26
  27. 27. 148.Thorsteinsdóttir H, Daar AS, Smith RD, Singer PA. Genomics – A Global Public Good? Lancet 2003; 361: 891-2. 149.Singer PA. Strengthening the role of ethics in medical education. Canadian Medical Association Journal 2003; 168: 854-5. 150.Workman S, McKeever P, Harvey WRC, Singer PA. Intensive Care Nurses’ and Physicians’ Experiences with Demands for Treatment: Some Implications for Clinical Practice. Journal of Critical Care 2003; 18: 17-24. 151.Rocker GM, Cook DJ, Martin DK, Singer PA. Seasonal Bed Closures in an Intensive Care Unit: A Qualitative Study. Journal of Critical Care 2003; 18: 25-30. 152.Singer PA, Wolfson MC. “The Best Places to Die”: Improving quality end of life care requires systematic and comprehensive information at the population level. British Medical Journal 2003; 327: 173-4. [Editorial] 153.Daar AS, Dowdeswell E, Singer PA. Genome Diplomacy: Canada’s Crucial Role. Policy Options 2003; 24(8): 56-61. 154.Martin DK, Walton N, Singer PA. Priority Setting in Surgery: Improve the Process and Share the Learning. World Journal of Surgery 2003; 27: 962-6. 155.Martin DK, Shuylman K, Santiago-Sorrell P, Singer PA. Priority Setting and Hospital Strategic Planning: A Qualitative Case Study. Journal of Health Services Research & Policy 2003; 8: 197-201. 156.Martin DK, Singer PA, Bernstein M. Access to intensive care unit beds for neurosurgery patients: A qualitative case study. Journal of Neurology, Neurosurgery & Psychiatry 2003; 74: 1299-303. 157.Varmus H, Klausner R, Zerhouni E, Acharya T, Daar AS, Singer PA. Grand Challenges in Global Health. Science 2003; 302: 398-9. 158.Robertson DW, Martin DK, Singer PA. Interdisciplinary research: Putting the methods under the microscope. BioMedCentral Medical Research Methodology 2003; 3: 20. 159.Martin DK, Hollenberg D, MacRae S, Madden S, Singer PA. Priority setting in a hospital drug formulary: a qualitative case study. Health Policy 2003; 66: 295-303. 160.Acharya T, Daar AS, Singer PA. Biotechnology and the UN’s millennium development goals. Nature Biotechnology 2003; 21: 1434-6. 161.Singer PA, Benatar SR, Bernstein M, Daar AS, Dickens BM, MacRae S, Upshur REG, Wright L, Zlotnik Shaul R. Ethics and SARS: Learning Lessons from the Toronto Experience. British Medical Journal 2003; 327: 1342-4. 162.Mielke J, Martin DK, Singer PA. Priority Setting in Critical Care: a Qualitative Case Study. Critical Care Medicine 2003; 31: 2764-8. 163.Court E, Daar AS, Martin E, Acharya T, Singer PA. Will Prince Charles et al diminish the opportunities of developing countries in nanotechnology? Nanotechnology 2004; V. 3:3. 27
  28. 28. 164.Martin DK, Singer PA. A Strategy to Improve Priority Setting in Health Care Institutions. Health Care Analysis, 2003; 11:59-68. 165.Ferris LE, Singer PA, Naylor CD. Better governance in academic health sciences centres: moving beyond the Oliveri/Apotex Affair in Toronto. Journal of Medical Ethics 2004; 30: 25-9. 166.Smith RD, Thorsteinsdóttir H, Daar A, Gold ER, Singer PA. Genomics knowledge and equity: a global public good. Bulletin of the World Health Organization 2004; 82: 385-9. 167.Acharya T, Kumar NK, Singer PA, Daar AS, Muthuswamy V. Harnessing genomics to improve health in India – an executive course to support genomics policy. Health Research and Policy Systems 2004; 2:1. 168.Daar AS, Bhatt A, Court E, Singer PA. Stem Cell Research and Transplantation: Science Leading Ethics. Transplantation Proceedings, 2004; 38(8): 2504-6. 169.Singer PA, on behalf of the British Medical Journal Ethics Committee. Consent to the publication of patient information. British Medical Journal, 2004; 329(7465): 566-8. 170.Powis J, Etchells E, Martin DK, MacRae SK, Singer PA. Can a “good death” be made better? A preliminary evaluation of a patient-centred quality improvement strategy for severely ill in-patients. BioMedCentral Palliative Care 2004; 3:2. 171.Thorsteinsdóttir H, Quach U, Martin DK, Daar AS, and Singer PA. Introduction: Promoting global health through biotechnology: An exploration of health biotechnology innovation systems in developing countries. Nature Biotechnology 2004; 22: DC3-7. 172.Ferrer M, Thorsteinsdóttir H, Quach U, Singer PA, and Daar AS. The scientific muscle of Brazil’s health biotechnology. Nature Biotechnology 2004; 22: DC8-12. 173.Zhenzhen L, Zhang J, Wen K, Thorsteinsdóttir H, Quach U, Singer PA, and Daar AS. Health biotechnology in China - the reawakening of a giant. Nature Biotechnology 2004; 22: DC13-8. 174.Thorsteinsdóttir H, Sáenz TW, Quach U, Daar AS, and Singer PA. Cuba – innovation through synergy. Nature Biotechnology 2004; 22: DC19-24. 175.Abdelgafar B, Thorsteinsdóttir H, Quach U, Singer PA, and Daar AS. The emergence of Egyptian biotechnology from generics. Nature Biotechnology 2004; 22: DC25-30. 176.Kumar NK, Quach U, Thorsteinsdóttir H, Somsekhar H, Daar AS, and Singer PA. Indian biotechnology - rapidly evolving and industry-led. Nature Biotechnology 2004; 22: DC31-6. 177.Motari M, Quach U, Thorsteinsdóttir H, Martin D, Daar AS, and Singer PA. South Africa – blazing a trail for African biotechnology. Nature Biotechnology 2004; 22: DC37-41. 178.Wong J, Quach U, Thorsteinsdóttir H, Singer PA, and Daar AS. South Korean biotechnology – a rising industrial and scientific powerhouse. Nature Biotechnology 2004; 22: DC42-7. 179.Thorsteinsdóttir H, Quach U, Martin D, Daar AS, and Singer PA. Conclusions: 28
  29. 29. promoting biotechnology innovation in developing countries. Nature Biotechnology 2004; 22: DC48-52. 180.Raja AJ, Singer PA. Transatlantic divide in publication of content relevant to developing countries. British Medical Journal 2004; 329: 1429-30. 181.Merali A, Boulyjenkov V, Singer PA, Daar AS. The ELSI Genetics Regulatory Resource Kit: A Tool for Policymakers in Developing Countries. Journal of Law, Medicine and Ethics 2004; 32: 692-700. 182.Isasi RM, Knoppers BM, Singer PA, Daar AS. Legal and Ethical Approaches to Stem Cell and Cloning Research: A comparative Analysis of Policies in Latin America, Asia and Africa. Journal of Law, Medicine and Ethics 2004; 32: 621-40. 183.Gibson JL, Martin DK, Singer PA, Setting priorities in health care organizations: criteria, processes, and parameters of success. BMC Health Services Research 2004, 4 (1): 25. 184. Acharya T, Kennedy R, Daar AS, Singer PA. Biotechnology to improve health in developing countries – a review. Memórias do Instituto Oswaldo Cruz 2004; 99 (4): 341-50. 185. Acharya T, Daar AS, Thorsteinsdóttir H, Dowdeswell E, Singer PA. Strengthening the role of genomics in global health. PLoS Medicine 2004; 1(3): E40. 186.Daar AS, Puja S, Singer PA. Genomics and Global Health: the work of the University of Toronto Joint Centre for Bioethics. Acta Bioethica 2004: v. 10(2): 213-4. 187.Reeleder D, Martin DK, Keresztes C, Singer PA. What do hospital decision-makers in Ontario, Canada, have to say about the fairness of priority setting in their institutions? BMC Health Services 2005; 5(1):8. 188.Smith AC, Mugabe J, Singer PA, Daar AS. Harnessing genomics to improve health in Africa – an executive course to support genomics policy. Health Research and Policy Systems 2005; 3(1):2. 189.Acharya T, Abdur Rab M, Singer PA, Daar AS. Harnessing genomics to improve health in the Eastern Mediterranean Region – an executive course in genomics policy. Health Research and Policy Systems 2005; 3(1):1. 190.Gibson JL, Martin DK, Singer PA. Evidence, economics and Ethics: Resource Allocation in Health Services Organizations. Healthcare Quarterly 2005; 8: 50-59. 191.Daar AS, Singer PA. Pharmacogenetics and Geographical Ancestry: Implications for Drug Development and Global Health. Nature Reviews Genetics 2005; 6: 241-6. 192.Robb A, Etchells E, Cusimano MD, Cohen R, Singer PA, McKneally MF. A Randomized trial of teaching bioethics to surgical residents. American Journal of Surgery 2005; 189(4): 453-7. 193. Morel C, Broun D, Dangi A, Elias C, Gardner C, Gupta RK, Haycock J, Heher T, Hotez P,Kettler H, Keusch G, Krattigner A, Kreutz F, Lee K, Mahoney R, Mashelkar RA, Min H, Matlin S, Mzimba M, Oehler J, Ridley R, Senanayake P, Thorsteinsdóttir H, Singer PA, Yun Mikyung. Health Innovation in Developing Countries to Address Diseases of 29
  30. 30. the Poor. Innovation Strategy Today 2005; 1: 1-15. 194. MacRae SK, Chidwick P, Berry S, Secker B, Hebert P, Shaul Zlotnik R, Faith K, Singer PA. Clinical Bioethics Integration, Sustainability and Accountability: The Hub and Spokes Strategy. Journal of Medical Ethics, 2005; 31: 256-61. 195. Gibson JL, Martin DK, Singer PA. Priority setting in hospitals: Fairness, inclusiveness, and the problem of institutional power differences. Social Science and Medicine 2005; 61: 2355-62. 196.Breslin JM, MacRae SK, Singer PA, Bell J. Top 10 Health Care Ethics ChallengesFacing the Public: Views of Toronto Bioethicists. BioMedCentral Medical Ethics 2005; 6: 5. 197.Court EB, Daar AS, Persad DL, Salamanca-Buentello F, Singer PA. Tiny technologies for the global good. Nanotoday 2005; April/May: 14-5. 198.Singer PA, Salamanca-Buentello F, Daar AS. Harnessing Nanotechnology to Improve Global Equity. Issues in Science and Technology 2005; Summer: 57-64. 199.Morel CM, Acharya T, Broun D, Dangi A, Elias C, Ganguly NK, Gardner CA, Gupta RK, Haycock J, Heher AD, Hotez PJ, Kettler HE, Keusch GT, Krattiger AF, Kreutz FT, Lall S, Lee K, Mahoney R, Martinez-Palomo A, Mashelkar RA, Matlin SA, Mzimba M, Oehler J, Ridley RG, Senanayake P, Singer PA, Yun M. Health Innovation Networks to Help Developing Countries Address Neglected Diseases. Science 2005; 309: 401-4. 200.Salamanca-Buentello F, Persad DL, Court EB, Martin DK, Daar AS, Singer PA. Nanotechnology and the Developing World. PLoS Medicine 2005; 2(4): 300-3. 201.Thorsteinsdóttir H, Sáenz TW, Singer PA, Daar AS. Different Rhythms of Health Biotechnology Development in Brazil and Cuba. Journal of Business Chemistry 2005; 2(3): 99- 106. 202.Benatar SR, Daar AS, Singer PA. Global Health Challenges: The need for an expanded discourse on bioethics. PLOS Medicine 2005; 2(7); e143. 203.Madden S, Martin DK, Downey S, Singer PA. Hospital Priority Setting with an Appeals Process: A qualitative case study and evaluation. Health Policy 2005; 73: 10-20. 204.Singer PA, Bhatt A, Frew S, Greenwood H, Persad DL, Salamanca-Buentello F, Séguin B, Taylor AD, Thorsteinsdóttir H, Daar AS. The Critical Role of Genomics in Global Health. Global Forum Update on Research for Health 2005; 2: 113-7. 205.Gibson JL, Mitton C, Martin DK, Donaldson C, Singer PA. Ethics and economics: Does programme budgeting and marginal analysis contribute to fair priority setting? Journal of Health Services Research & Policy 2006; 11: 32-7. 206.Dowdeswell E, Daar AS, Singer PA. Getting governance into genomics. Science and Public Policy 2005; 32(6): 497-8. 207. Singer PA, Daar AS, Salamanca-Buentello F, Court E. Nano-Diplomacy. Georgetown Journal of International Affairs 2006; Winter/Spring: 129-37. 30
  31. 31. 208.Thorsteinsdóttir H, Daar AS, Singer PA, Archambault É, Arunachalam S. Health biotechnology publishing takes-off in developing countries. International Journal of Biotechnology 2006; 8(1/2): 23-42. 209.Quach U, Thorsteinsdóttir H, Renihan J, Bhatt A, Von Aesch ZC, Singer PA, Daar AS. Biotechnology patenting takes off in developing countries. International Journal of Biotechnology 2006; 8(1/2): 43-59. 210.Dowdeswell E, Singer PA, Daar AS. Increasing human security through biotechnology. International Journal of Biotechnology 2006; 8(1/2): 119-31. 211.Dowdeswell E, Daar AS, Acharya T, Singer PA. Realising the promise of genomics: exploring governance. International Journal of Biotechnology 2006; 8(1/2): 132-41. 212.Persad DL, Quach U, Thorsteinsdóttir H, Salamanca-Buentello F, Singer PA, Daar AS. Enabling knowledge societies in developing countries: the example of genomics. International Journal of Biotechnology 2006; 8(1/2): 4-22. 213.Greenwood HL, Thorsteinsdóttir H, Perry G, Renihan J, Singer PA, Daar AS. Regenerative medicine: new opportunities for developing countries. International Journal of Biotechnology 2006; 8(1/2): 60-77. 214.Séguin B, State L, Singer PA, Daar AS. Scientific diasporas as an option for brain drain: re-circulating knowledge for development. International Journal of Biotechnology 2006; 8(1/2): 78-90. 215. Mackie JE, Taylor AD, Daar AS, Singer PA. Corporate social responsibility strategies aimed at the developing world: perspectives from bioscience companies in the industrialised world. International Journal of Biotechnology 2006; 8(1/2): 103-18. 216.Frew SE, Sammut SM, Siu WW, Daar AS, Singer PA. The role of the domestic private sector in developing countries for addressing local health needs. International Journal of Biotechnology 2006; 8(1/2): 91-102. 217.Wilson K, McDougall C, Upshur R, the Joint Centre for Bioethics SARS Global Health Ethics Research Group (Daar AS, Singer PA, Tracy CS). The New International Health Regulations and the Federalism Dilemma. PLoS Medicine 2006; 3(1): e1. 218.Mackie JE, Taylor AD, Finegold DL, Daar AS, Singer PA. Lessons on Ethical Decision- Making from the Bioscience Industry. PLoS Medicine 2006; 3(5): e129. 219.Singer PA, Guyatt GH. Deeper lessons from the CMAJ debacle. Lancet 2006; 367: 1551-3. 220.Séguin B, Singer PA, Daar AS. Scientific Diasporas. Science 2006; 312: 1602-3. 221.Reeleder D, Martin DK, Goel V, Singer PA. Leadership and Priority Setting: The Perspective of Hospital CEOs. Health Policy, 2006; 79 (1), 24-34. 222.Walton NA, Singer PA, Martin DK, Peter E, Pringle D. Priority Setting and Cardiac Surgery: A Qualitative Study. Health Policy, 2006 Jun 3; 80 (2007) 444-458. 223.Wilson K, Singer PA (for the Joint Centre for Bioethics SARS Global Health Ethics 31
  32. 32. Research Group). Travel Advisories and the Next Pandemic. Human Security Bulletin (Human Security and Health edition). July, 2006. 224.Secker B, Goldenberg MJ, Gibson BE, Wagner E, Parke B, Breslin J, Thompson A, Lear JR, Singer PA. Just regionalisation: rehabilitating care for people with disabilities and chronic illnesses. BMC Med Ethics. 2006 Aug 29; 7 (1): E9. 225.Greenwood HL, Singer PA, Downey GP, Martin DK, Thorsteinsdottir H, Daar AS. Regenerative Medicine and the Developing World. PLoS Medicine. 2006; 3 (9) 1496-1500 226. Edgell D, Dipchand A, Harrison C, Singer PA. Cross Border Shopping: How much for your Heart? Healthcare Quarterly. 2006; 9 (4): 81-83. 227.Singer PA, Court EB, Bhatt A, Frew SE, Greenwood H, Persad DL, Salamanca-Buentello F, Séguin B, Taylor AD, Thorsteinsdottir H and Daar AS. Applying Genomics-related Technologies for Africa’s Health Needs. African Journal of Medicine and Medical Sciences. 2007; 36. Suppl: 7-14 Review. 228.Reeleder D, Goel V, Singer PA, Martin D. “Accountability agreements in Ontario hospitals: Are they fair?” Journal of Public Administration Research and Theory. 2006; mul024v1. 229.Thorsteinsdottir H, Daar A, Singer PA. Innovation Cultures in Developing Countries: The Case of Health Biotechnology, Comparative Technology Transfer and Society. (5) 2; August 2007: 178-201 230.Frew SE, Rezaie R, Sammut SM, Ray M, Daar AS, Singer PA. India’s Home-Grown Health Biotechnology Sector at a Crossroads. Nature Biotechnology, April 2007; 25 (4): 403-417. 231.Singer PA, Taylor AD, Daar AS, Upshur REG, Singh JA, Lavery, JV. Grand Challenges in Global Health: The Ethical, Social and Cultural Program. PLOS Medicine Vol 4, No. 9, e 265. doi:10.1371/journal.pmed.o040265. September 2007. 232.Berndtson K, Daid T, Tracy CS, Bhan A, Cohen ERM, Upshur REG, Singh JA, Daar AS, Lavery JV, Singer PA. Grand Challenges in Global Health: Ethical, Social, and Cultural Issues based on Key Informant Perspectives. PLOS Medicine Vol 4, No. 9, e 268. doi:10.1371/journal.pmed.o040265. September 2007. 233.Bhan AL, Singh JA, Upshur REG, Singer PA, Daar AS. Grand Challenges in Global Health: Engaging Civil Society Organization in Biomedical Research in Developing Countries. PLOS Medicine Vol. 4, No. 9, e272 doi:10.1371/journal.pmed.0040272. September 2007 234.Tindana PO, Singh JA, Tracy SC, Upshur REG, Daar AS, Singer PA, Frohlich, J, Lavery JV. Grand Challenges in Global Health: Community Engagement in Research in Developing Countries. PLOS Medicine Vol.4, No. 9, e273 doi:10.1371/journal.pmed.0040273. September 2007. 235.Singer PA, Berndtson K, Tracy SC, Cohen ERM, Masum H, Daar AS, Lavery JV. A tough transition. Nature, Vol 449, 160-163. September 2007. 236.Taylor AD, Brook D, Watters D, Dowdeswell E, Daar AS, Singer PA. North-South 32
  33. 33. Partnerships – A study of Canadian Firms. Nature Biotechnology 25(9), 978-9. September 2007. 237.Singer PA, Masum H. A Visual Dashboard for Moving Health Technologies From “Lab to Village”. Journal of Medical Internet Research, 9 (4) :e32; 2007 238.Masum H, Daar AS, Al-Bader S, Shah R, and Singer PA. Accelerating Health Product Innovation in Sub-Saharan Africa. Innovations (MIT Press), Vol 2 (4) pp. 151-171. Fall 2007. 239.Daar AS, Berndtson K, Persad D, Singer PA. How can developing countries harness biotechnology to improve health? BMC Public Health 2007, 7:346 doi:10.1186/1471-2458-7-346 240.Daar AS, Singer PA, Persad D, Pramming S, Matthews D, Beaglehole R, Bernstein A, Borysiewicz L, Colagiuri S, Ganguly N, Glass R, Finewood D, Koplan J, Nabel E, Sarna G, Sarrafzadegan N, Smith R, Yach D, Bell J. Grand Challenges in Chronic Non- Communicable Diseases. Nature, November 2007;Vol 450, pp. 494-496. 241.Singer PA, Motivating Action: Why should Canadian Physicians participate in research, education or patient care in the developing world? Canadian Family Physician, 2007; 53 (11): 1849-1851 (Eng). 242.Frew S, Sammut S, Shore A, Ramjist J, Al-Bader S, Rezaie R, Daar A, Singer PA. Chinese health biotech and the billion-patient market. Nature Biotechnology, 26, 37-53 (2008). 243.Seguin B, Hardy B, Singer PA, Daar AS. Bidil: Recontextualizing the Race Debate. The Pharmacogenomics Journal, January 2008; 8(3): 169-173 244.Reeleder D, Goel V, Singer PA, Martin D. Accountability agreements in Ontario hospitals: Are they fair? Journal of Public Administration Research and Theory, 2008; 18: p. 161-175. 245.Cohen ER, Masum H, Berndtson K, Saunders V, Hadfield T, Panjwani D, Persad DL, Minhas GS, Daar AS, Singh JA, Singer PA. Public engagement on global health challenges. BMC Public Health. 2008 May 20;8:168. 246.Frew S, Kettler H, Singer PA. The Indian and Chinese Health Biotechnology Industries: Champions of global health? Health Affairs . 2008 Jul-Aug;27(4):1029-41. 247.Silva Diego S, Gibson JL, Sibbald R, Connolly E, Singer PA. Clinical ethicists’ perspectives on organizational ethics in health care organizations. Journal of Medical Ethics, 2008; 34 pp320-323 doi: 10.1136/jme.2007.020891 248.Seguin B, Hardy B, Singer PA, Daar AS. Genomic Medicine and Developing Countries: creating a Room of their own. Nature Reviews Genetics, June 2008 (9) pp 487-493. 249.Rezaie R, Frew S, Sammut S, Maliakkal M, Daar AS, Singer PA. Brazilian health biotech--fostering crosstalk between public and private sectors. Nature Biotechnology June 2008 Vol 26; (6) pp 627-644 250.Hardy, B., Seguin, B., Mukerji, M., Singer PA., Brahmachari, SK., Daar, AS. (2008) From diversity to delivery: the case of the Indian Genome Variation initiative. Nature 33
  34. 34. Reviews Genetics. 9(10): s9-s13 251.Seguin, B., Hardy, B., Singer PA, Daar, AS. (2008) Genomics, public health, and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN). Nature Reviews Genetics. 9(10): s5-s8 252.Hardy, B., Seguin, B., Ramesar, R., Singer PA, Daar, AS. (2008) South Africa: from species cradle to genomic applications. Nature Reviews Genetics 9(10): s19-s22 253.Seguin, B., Hardy, B., Singer PA, Daar, AS. (2008) Universal health care, genomic medicine and Thailand: investing in today and tomorrow Nature Reviews Genetics 9(10) :s14-s18 254.Seguin, B., Hardy, B., Singer PA, Daar, AS. (2008) Human genomic variation initiatives in emerging economies and developing countries Nature Reviews Genetics 9(10) :s3-s4 255.Hardy, B., Seguin, B., Goodsaid, F., Jimenez-Sanchez, G., Singer PA, Daar, AS. The next steps for genomic medicine: challenges and opportunities for the developing world. Nature Reviews Genetics, 2008, vol. 9(10) :s23-s27 256.Lander B, Thorsteinsdóttir H, Singer PA, Daar AS. Harnessing stem cells for health needs in India. Cell Stem Cell, July 2008, 3;3(1):11-5. 257.Rosenberg-Yunger ZR, Daar AS, Singer PA, Martin DK. Healthcare sustainability and the challenges of innovation to biopharmaceuticals in Canada. Health Policy, 2008 Sep;87(3):359-68. 258.Singer PA and Abdallah S Daar with Sara Al-Bader, Ronak Shah, Ken Simiyu, Ryan E Wiley, Pamela Kanellis, Menaka Pulandiran and Marilyn Heymann: Commercializing African Health Research: Building Life Science Convergence Platforms. Global Forum Update on Research for Health, October 2008, vol. 5 pp 143-150 259.Sheila Kamunyori, Sara Al-Bader, Ronak Shah, Ken Simiyu, Singer PA, Daar AS. Accelerating African Health Innovation. Africa Journal, March 2008 pp 20-21 260.Melon CC, Ray M, Chakkalackal S, Li M, Cooper JE, Chadder J, Ke W, Li L, Madkour MA, Aly S, Adly N, Chaturvedi S, Konde V, Daar AS, Singer PA, Thorsteinsdottir H. A Survey of South-North Health Biotech Collaboration. Nature Biotechnology, March 2009, vol. 27 Number 3, pp: 229-232 261.Sibbald SL, Singer PA, Upshur RU, Martin DK. Priority setting: what constitutes success? A conceptual framework for successful priority setting. BMC Health Services Research March 5 2009, 9:43 262.Singer PA, Abdallah S. Daar. How biodevelopment can enhance biosecurity. The Bulletin of the Atomic Scientists, March/April 2009, vol. 65, no. 2, pp. 23-30, 263.Lavery JV, Singer PA, Ridzon R. Singh JA, Slutsky AS, Anisko JJ, Buchanan D. In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs? PLoS Med, June 9, 2009, 9;6 (6):e 1000071. 264.Al-Bader S, Frew SE, Essajee I, Liu VY, Daar AS, Singer PA. Small but tenacious: South 34
  35. 35. Africa's health biotech sector. Nature Biotechnology, May 2009, vol. 27, no. 5, pp. 427-45 265.Singh JA, Bandewar S, Singer PA, Sex, Gender, and Health Biotechnology: points to consider. BMC International Health and Human Rights 2009, 9:15doi:10.1186/1472-698X-9-15 266.Omobowale EB, Singer PA and Daar AS. The three main monotheistic religions and gm food technology: an overview of perspectives. BMC international health and human rights, August 2009, 9:18. 267.Ray M, Daar AS, Singer PA, Thorsteinsdóttir H. Globetrotting firms: Canada's health biotechnology collaborations with developing countries. Nature Biotechnology, vol. 27, no. 9, pp. 806-14, September 2009 268.Obidima Ezezika, Fiona Thomas, Jim Lavery, Daar AS, Singer PA. A Social Audit Model for Agro-biotechnology Initiatives in Developing Countries: Accounting for Ethical, Social, Cultural, and Commercialization Issues, J. Technol. Manag. Innov. 2009, Volume 4, Issue 3, Received August 10, 2009 / Accepted September 21, 2009 269.Frew SE, Liu VY, Singer PA. A Business Plan to Help the Global South in its Fight Against Neglected Diseases. Health Affairs, 2009, vol.28, no.6,pp.1760-1773 270.McMahon DS, Thorsteinsdóttir H, Singer PA, Daar AS. Cultivating regenerative medicine innovation in China. Regen. Med. 2010 5(1), 35–44. 271.Singer PA, Daar AS. MaRS Africa. Scientific American Global Health. (in press) 272.Masum H, Ranck J, Singer PA. Five promising methods for health foresight. Foresight Journal. 2010, vol 12, no 1, pp.54 – 66 273.Benatar R S, Singer PA. Responsibilities in international research: a new look revisited J Med Ethics, 2010, vol 36. pp. 194-197 274.Sibbald S, Gibson J, Martin D, Singer PA, Upshur R. Evaluating Priority Setting Success in Healthcare: A Pilot Study. BMC Health Services Research (in press) 275.Emerson C, Singer PA. Is there an ethical obligation to complete polio eradication? The Lancet, April 17, 2010, vol. 375. pp. 1340-1341. 14. Book Chapters 1.Singer PA. Undergraduate Medical Ethics: Why? What? In: Baylis F, Downie J, eds. Medical Ethics for Undergraduate Medical Students: Symposium 1989 Proceedings. London: Westminster Institute, 1990, pp. 9-24. 2.Singer PA, Lantos JD, La Puma J, Siegler M. Ethical issues in cardiopulmonary transplantation. In: Kapoor AS, Laks H, Schroeder JS, Yacoub MH, eds. Cariomyopathies and Heart-Lung Transplantation. New York: McGraw Hill, 1990, pp. 471-82. 3.Singer PA, Siegler M. Decisions to forego life-sustaining treatment. In: Kassirer JP, ed. 35
  36. 36. Current Therapy in Internal Medicine, 3rd edition. Philadelphia: B.C. Decker, 1991, pp. 98-103. 4.Siegler M, Singer PA. Clinical Ethics. In: Kelley W, et al., eds. Textbook of Internal Medicine, 2nd edition, Volume 1, 1992, pp. 3-5. 5.Siegler M, Singer PA. Clinical Ethics in the Practice of Medicine. In: Bennett JC, et al., eds. Cecil Textbook of Medicine, 19th edition. Philadelphia: W.B. Saunders Company, 1992. 6.Martin DK, Singer PA, Siegler M. Ethical Considerations in Live Donor Lung Transplantation. In: Kern JA, Kron IL, eds. Reduced-size Lung Transplantation. Austin: R.G. Landes, 1993, pp. 88-97. 7.Singer PA, Siegler M. Clinical Ethics in the Practice of Medicine. In: Bennett JC, ed. Cecil Textbook of Medicine, 20th edition. Philadelphia: W.B. Saunders Company, 1995, pp. 4-6. 8.Caplan A, Siegler M, Singer PA. Clinical Ethics. In: Kelley W, et al., eds. Textbook of Internal Medicine, 3rd edition. Philadelphia: Lippincott-Raven Publishers, 1997, pp. 6-7. 9.Kodish E, Singer PA, Siegler M. Ethical Issues in Clinical Oncology. In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 5th edition. Philadelphia: J.B. Lippincott Co., 1997, pp. 2973-82. 10.Singer PA, Martin DK. Improving Dying in Canada. In: Canada Health Action: Building on the Legacy -- Papers Commissioned by the National Forum on Health, Volume 3: Settings and Issues. Ottawa: National Forum on Health, 1998, pp. 479-529. 11.Singer PA. Preface. In: Singer PA, ed. Bioethics at the Bedside: A Clinician's Guide. Ottawa: Canadian Medical Association, 1999, pp. ix-x. 12.Etchells E, Sharpe G, Walsh P, Williams JR, Singer PA. Consent. In: Singer PA, ed. Bioethics at the Bedside: A Clinician's Guide. Ottawa: Canadian Medical Association, 1999, pp. 1-7. 13.Etchells E, Sharpe G, Burgess M, Singer PA. Disclosure. In: Singer PA, ed. Bioethics at the Bedside: A Clinician's Guide. Ottawa: Canadian Medical Association, 1999, pp. 9-16. 14.Etchells E, Sharpe G, Elliott C, Singer PA. Capacity. In: Singer PA, ed. Bioethics at the Bedside: A Clinician's Guide. Ottawa: Canadian Medical Association, 1999, pp. 17-24. 15.Etchells E, Sharpe G, Dykeman MJ, Meslin EM, Singer PA. Voluntariness. In: Singer PA, ed. Bioethics at the Bedside: A Clinician's Guide. Ottawa: Canadian Medical Association, 1999, pp. 25-31. 16.Lazar N, Greiner GG, Robertson G, Singer PA. Substitute Decision Making. In: Singer PA, ed. Bioethics for Clinicians. Ottawa: Canadian Medical Association, 1999, pp. 33-7. 17.Singer PA, Robertson G, Roy DJ. Advance Care Planning. In: Singer PA, ed. Bioethics at the Bedside: A Clinician's Guide. Ottawa: Canadian Medical Association, 1999, pp. 39-46. 18.Hébert PC, Hoffmaster B, Glass KC, Singer PA. Truth Telling. In: Singer PA, ed. 36

×